Song Qing-Kun, Wang Xiao-Li, Zhou Xin-Na, Yang Hua-Bing, Li Yu-Chen, Wu Jiang-Ping, Ren Jun, Lyerly Herbert Kim
Beijing Key Laboratory of Therapeutic Cancer Vaccine, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing, People's Republic of China; Duke University Medical Center, Durham, North Carolina, USA.
Beijing Key Laboratory of Therapeutic Cancer Vaccine, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing, People's Republic of China; Duke University Medical Center, Durham, North Carolina, USA
Oncologist. 2015 Jul;20(7):773-9. doi: 10.1634/theoncologist.2014-0351. Epub 2015 May 22.
As one of its responses to the increasing global burden of breast cancer (BC), China has deployed a national registration and BC screening campaign. The present report describes these programs and the initial results of these national BC control strategies, highlighting the challenges to be considered.
The primary BC incidence and prevalence data were obtained from the Chinese National Central Cancer Registry. MapInfo software was used to map the geographic distribution and variation. The time trends were estimated by the annual percentage of change from 2003 to 2009. The description of the screening plans and preliminary results were provided by the Ministry of Health.
Chinese cancer registries were primarily developed and activated in the East and Coastal regions of China, with only 12.5% of the registries located in West China. Geographic variation was noted, with the incidence of BC higher in North China than in South China and in urban areas compared with rural areas. Of great interest, these registries reported that the overall BC incidence has been increasing in China, with an earlier age of onset compared with Western countries and a peak incidence rate at age 50. In response to this increasing incidence and early age of onset, BC screening programs assessed 1.46 million women aged 35-59 years, using clinical breast examinations and ultrasound as primary screening tools between 2009 and 2011. The diagnostic rate for this screening program was only 48.0/10(5) with 440 cases of early stage BC. Early stage BC was detected in nearly 70% of screened patients. Subsequently, a second-generation screening program was conducted that included older women aged 35-64 years and an additional 6 million women were screened.
The cancer registration system in China has been uneven, with a greater focus on East rather than West China. The data from these registries demonstrate regional variation, an increasing BC incidence, and an early age of onset. The 2009 to 2011 BC screening program targeting women aged 35-59 years had a low detection rate that resulted in a second-generation screening program that extended the cohort size and ages screened to 35-64 years.
Cancer registration has been active in China for decades; however, a national survey of registries has not been routinely reported. This study used MapInfo to describe the reported data and found asymmetric registration activities, geographic variations in breast cancer (BC) burdens, and an increasing incidence with a peak at age 50. The initial Chinese BC screening programs focused on a relatively young population of women aged 35-59 years and had a low detection rate, but 69.7% of patients had early stage BC. Older women were included in the second-generation screening programs, and an additional 6 million women were screened. Consideration of regional variations and age is necessary to optimize the efficiency and utility of BC screening in China, with the ultimate goal to reduce BC mortality.
作为应对全球乳腺癌(BC)负担日益加重的举措之一,中国开展了一项全国性的登记和乳腺癌筛查活动。本报告介绍了这些项目以及这些全国性乳腺癌控制策略的初步成果,强调了需要考虑的挑战。
主要的乳腺癌发病率和患病率数据来自中国国家癌症中心。使用MapInfo软件绘制地理分布和变化情况。通过计算2003年至2009年的年变化百分比来估计时间趋势。筛查计划和初步结果的描述由卫生部提供。
中国的癌症登记处主要在中国东部和沿海地区建立并启用,只有12.5%的登记处位于中国西部。注意到存在地理差异,中国北方的乳腺癌发病率高于南方,城市地区高于农村地区。有趣的是,这些登记处报告称,中国乳腺癌的总体发病率一直在上升,发病年龄比西方国家更早,发病高峰年龄为50岁。针对这一发病率上升和发病年龄提前的情况,2009年至2011年期间,乳腺癌筛查项目对146万名35至59岁的女性进行了评估,主要使用临床乳腺检查和超声作为筛查工具。该筛查项目的诊断率仅为48.0/10万,发现了440例早期乳腺癌病例。近70%的筛查患者被检测出患有早期乳腺癌。随后,开展了第二代筛查项目,纳入了35至64岁的老年女性,又有600万女性接受了筛查。
中国的癌症登记系统不均衡,更多地集中在东部而非西部。这些登记处的数据显示出地区差异、乳腺癌发病率上升以及发病年龄提前。2009年至2011年针对35至59岁女性的乳腺癌筛查项目检测率较低,因此开展了第二代筛查项目,扩大了筛查人群规模并将年龄范围扩大到35至64岁。
癌症登记在中国已经开展了几十年;然而,尚未定期报告全国性的登记处调查情况。本研究使用MapInfo来描述报告的数据,发现登记活动不对称、乳腺癌(BC)负担存在地理差异、发病率上升且发病高峰年龄为50岁。中国最初的乳腺癌筛查项目主要针对35至59岁相对年轻的女性群体,检测率较低,但69.7%的患者患有早期乳腺癌。第二代筛查项目纳入了老年女性,又有600万女性接受了筛查。在中国,考虑地区差异和年龄对于优化乳腺癌筛查的效率和效用至关重要,最终目标是降低乳腺癌死亡率。